CODING

 
CPT Code (Product): 90750
CPT Code (Administration)
1 vaccine administered:

90471
Each additional vaccine administered during same encounter: 90472
ICD-10-CM Code (Encounter for Immunization): Z23
Administration Modifier for Medicare: GY
MVX Code: SKB
CVX Code: 187*

 

*

The CDC also created CVX code 188 for "zoster vaccine, unspecified formulation" to facilitate transmission of administration data
when the exact formulation of the vaccine is not known (such as when recording data from a vaccination card).

CDC=Centers for Disease Control and Prevention.

HOW SHINGRIX IS SUPPLIED

Medicine Bottle Dosage Icon 1x

SHINGRIX is supplied as an outer package of 1 dose (NDC 58160-819-12) containing:

Adjuvant Suspension Component (Vial 1 of 2) NDC 58160-829-01

Lyophilized gE Antigen Component (Vial 2 of 2) NDC 58160-828-01

Medicine Bottle Dosage Icon 10x

SHINGRIX is supplied as an outer package of 10 doses (NDC 58160-823-11) containing:

Adjuvant Suspension Component (10 vials) NDC 58160-829-03

Lyophilized gE Antigen Component (10 vials) NDC 58160-828-03

gE=glycoprotein E.


Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

All trademarks are the property of their respective owners.

1004182R0 April 2018